浏览全部资源
扫码关注微信
1.天津市儿童医院/天津大学儿童医院药剂科,天津 300134
2.首都医科大学附属北京儿童医院药学部,北京 100045
药师,硕士。研究方向:药剂学。电话:022-87787305。E-mail:zjfyouyou@163.com
主任药师,硕士生导师,硕士。研究方向:药事管理。电话:022-87787305。E-mail:syytjcn@sina.com
纸质出版日期:2022-11-15,
收稿日期:2022-05-05,
修回日期:2022-09-21,
扫 描 看 全 文
张金芬,佟若菲,黄涛等.国内外儿童非处方药(化学药品)剂型与规格的比较分析 Δ[J].中国药房,2022,33(21):2561-2565.
ZHANG Jinfen,TONG Ruofei,HUANG Tao,et al.Comparative analysis of the dosage forms and specifications of OTC (chemical drugs) for children at home and abroad[J].ZHONGGUO YAOFANG,2022,33(21):2561-2565.
张金芬,佟若菲,黄涛等.国内外儿童非处方药(化学药品)剂型与规格的比较分析 Δ[J].中国药房,2022,33(21):2561-2565. DOI: 10.6039/j.issn.1001-0408.2022.21.01.
ZHANG Jinfen,TONG Ruofei,HUANG Tao,et al.Comparative analysis of the dosage forms and specifications of OTC (chemical drugs) for children at home and abroad[J].ZHONGGUO YAOFANG,2022,33(21):2561-2565. DOI: 10.6039/j.issn.1001-0408.2022.21.01.
目的
2
对国内外儿童非处方药(OTC)(化学药品)剂型与规格的现状进行比较分析,为新增我国儿童OTC剂型与规格提供参考。
方法
2
梳理我国儿童OTC单方制剂的活性成分,比较我国与世界卫生组织(WHO)发布的第8版《WHO儿童基本药物示范目录》(WHO EMLc)及美/英/欧(本文指欧盟国家)/日具有相同活性成分的儿童OTC剂型与规格的异同并进行分析。
结果
2
我国儿童OTC单方制剂对应的活性成分共计72个,涉及34种剂型、216个规格;在WHO EMLc及美/英/欧/日儿童OTC中共检索到39个相同活性成分,涉及38种剂型、258个规格。在39个相同活性成分对应的儿童OTC中,我国的特有剂型有10种,WHO EMLc及美/英/欧/日的特有剂型共计16种,后者收录的部分具有儿童使用优势的剂型(咀嚼软糖、局部皮肤用凝胶剂、口服液体喷雾剂等)在我国暂未收录;我国的特有规格有107个,WHO EMLc及美/英/欧/日的特有规格共计214个,后者药品规格适用年龄段的划分更为细致。此外,少数活性成分(如布洛芬、盐酸西替利嗪等)对应的剂型与规格在我国未纳入儿童OTC,而英/欧已纳入。
结论
2
WHO EMLc及美/英/欧/日儿童OTC的剂型与规格在整体上较我国更丰富和灵活。我国相关部门应借鉴WHO和国外先进经验,加大对儿童OTC剂型与规格的研发。
OBJECTIVE
2
To compare the dosage forms and specifications of over-the-counter drug (OTC) (chemical drugs) for children at home and abroad, and to provide reference for the addition of new dosage forms and specifications of OTC for children in China.
METHODS
2
Data analysis was used to comb the active ingredients of OTC single-ingredient preparation for children in China. The similarities and differences of the dosage forms and specifications of OTC for children with the same active ingredients among China and 8th edition of
WHO Model List of Essential Medicines for Children
(WHO EMLc) and US/UK/EU (this article refers specifically to EU countries)/Japan were analyzed by comparative analysis.
RESULTS
2
There were 72 active ingredients of OTC single-ingredient preparation for children in China, corresponding to 34 dosage forms and 216 specifications; 39 same active ingredients of OTC for children were retrieved in WHO EMLc and US/UK/EU/Japan, corresponding to 38 dosage forms and 258 specifications. Among OTC for children corresponding to 39 active ingredients, there were 10 unique dosage forms in China, and 16 unique dosage forms in WHO EMLc and US/UK/EU/Japan, of which some dosage forms have advantages for children (such as chewing gums, gels for external use, spray for oral liquid, etc.), were included in the latter while not included in China. There were 107 unique specifications in China, and 214 unique specifications in WHO EMLc and US/UK/EU/Japan, of which the division of applicable age groups for specifications was more detailed. In addition, the dosage forms and specifications corresponding to a few active ingredients (such as ibuprofen, cetirizine hydrochloride) were not included in OTC for children in China, while included in UK/EU.
CONCLUSIONS
2
The dosage forms and specifications of OTC for children in WHO EMLc and US/UK/EU/Japan are generally more abundant and flexible than in China. Relevant departments in China should learn from the advanced experience of WHO and foreign countries and increase the research and development of dosage forms and specifications of OTC for children.
儿童非处方药活性成分剂型规格
over-the-counter drugactive ingredientsdosage formsspecifications
张圣雨,陈泳伍.服用OTC药物,牢记四要点[J].大众健康,2021(9):62-63.
任静朝,张光辉,段广才,等.城乡儿童自我药疗现状及影响因素分析[J].中国现代医学杂志,2017,27(25):42-48.
石双姣,沈志莹,段应龙,等.儿童居家用药安全的研究进展[J].护理学杂志,2019,34(1):95-99.
国家统计局.第七次全国人口普查公报:第五号[EB/OL].(2021-05-11)[2022-09-09].http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.htmlhttp://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
张靖,秦丹,靳洪涛.儿童用药安全研究评价体系的初步思考[J].中国药物警戒,2017,14(11):657-661.
张笑雨.儿药销售:专业致胜、品牌第一[J].中国药店,2017(3):68.
国家药品监督管理局.国家药品编码本位码:截至2022年6月30日[EB/OL].(2022-07-19)[2022-09-09]. http://www.nmpa.gov.cn/zwfw/zwfwzxfw/zxfwsjxz/202207191- 35616162.htmlhttp://www.nmpa.gov.cn/zwfw/zwfwzxfw/zxfwsjxz/202207191-35616162.html.
许淑红,张绮,张林琦,等.探讨我国儿科用药的发展现状及政策层面的思考[J].中国临床药理学杂志,2020,36(12):1760-1767.
王雪韵,苏巍巍,丁宏,等.我国儿童药品在临床使用中存在的问题及对策分析[J].中国药房,2019,30(2):149-153.
MATULYTE I,MARKSA M,BERNATONIENE J. Deve- lopment of innovative chewable gel tablets containing nutmeg essential oil microcapsules and their physical properties evaluation[J]. Pharmaceutics,2021,13(6):873.
黄辉,郑崇光,张楠,等.不同剂量开喉剑喷雾剂(儿童型)治疗手足口病临床疗效比较[J].中国药业,2017,26(5):56-58.
何琪莹.局部药用凝胶剂的研究新进展和新应用[J].中国药物与临床,2006,6(5):384-387.
秦倩倩,张云霞,赵瑞玲.儿童用药规格现况研究[J].中国药物与临床,2021,21(19):3327-3329.
刘元江,李翠翠. 30种儿童非处方药口服液体制剂分剂量的调查分析[J].儿科药学杂志,2021,27(1):41-45.
国家药品监督管理局.国家药品不良反应监测年度报告:2021年[EB/OL].(2022-03-30)[2022-09-09]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20220329161925106.htmlhttps://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20220329161925106.html.
张梦娟,孙一帆,金美兰,等.儿童家庭用药安全现状及影响因素[J].科技视界,2017(11):192,200.
洪峻,谭萌萌,王晓玲,等.中国与日本儿童用药政策比较[J].中国药业,2022,31(13):7-11.
何淑旺,邱琼. 欧盟儿童药品管理的经验及启示[J].中国药物评价,2013,30(5):298-301.
岳志华,王晓玲,张伟,等.美国儿童用药法规、实施成效及启示[J].临床药物治疗杂志,2020,18(9):83-87.
李文君,卢梦情,徐蔼琳,等.国内外不同年龄段儿童用药剂型的比较与思考[J].中国医院药学杂志,2019,39(21):2236-2239.
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构